Tirzepatide delivers 5.19 kg greater weight loss than semaglutide, with more serious adverse events.

Obesity and type 2 diabetes mellitus (T2DM) are pressing global health challenges. Current standard-of-care often falls short in achieving sustained weight loss and glycemic control. Tirzepatide, a dual GIP/GLP-1 receptor agonist, and semaglutide, a selective GLP-1 receptor agonist, are leading incretin therapies. While both are highly effective, a pooled comparison of their direct head-to-head efficacy and safety was needed to guide clinical decisions and understand their relative benefits.

Researchers conducted a systematic review and meta-analysis, searching PubMed, Embase, and ScienceDirect up to February 2026 for head-to-head studies comparing tirzepatide and semaglutide. Three studies were included in the final analysis. Mean differences (MD) and risk ratios (RR) were pooled using a random-effects model, with I2 statistics used to measure heterogeneity. Primary endpoints included changes in body weight and the incidence of adverse events.

The meta-analysis of three studies revealed that tirzepatide led to a significantly greater reduction in weight compared to semaglutide. The pooled mean difference for weight loss was -5.19 kg (95% CI: -7.96 to -2.42; p = 0.0002; I2 = 88.5%). This translated to a 1.50-fold increased possibility of achieving ≥10% weight loss with tirzepatide (pooled RR = 1.50, 95% CI: 1.15-1.96; p = 0.0069; I2 = 86.3%). No significant differences were observed in overall adverse events or gastrointestinal-specific events between the two treatments. However, a notable finding was the increased incidence of serious adverse events with tirzepatide.

Tirzepatide was associated with a 1.83-fold higher risk of serious adverse events (RR = 1.83, 95% CI: 1.18-2.85; p = 0.007).